# Nadav Rosenberg

> Nadav Rosenberg is a seed investor in London backing Software and Biotechnology. See 15 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Location: London, United Kingdom
- Total investments: 15
- Last investment: Aug 2023
- Lead investor: 7%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/in/nadavrosenberg
- X (Twitter): https://twitter.com/nadavrosenberg?lang=en
- Website: https://x.com/nadavrosenberg?lang=en

Nadav Rosenberg is a seed investor in London focused on Software and Biotechnology. Nadav leads Taboola’s expansion and operations in Europe and Australia.Prior to joining Taboola, Nadav was a member of the founding team of Groupon UK & IR, taking part in building and managing Groupon’s business in the UK.Before joining Groupon, Nadav worked as a strategy consultant with McKinsey & Company in London.Nadav isbased in London and holds an MBA from INSEAD, France.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $850k–$3.1M |
| Pre-Seed | $2M–$2M |
| Series A | $18M–$21M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 5 | 33% |
| Biotechnology | 5 | 33% |
| Artificial Intelligence | 5 | 33% |
| Machine Learning | 4 | 27% |
| Life Science | 3 | 20% |

27 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 10 | 67% |
| Pre-Seed | 2 | 13% |
| Series A | 2 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 7 | 47% |
| France | 1 | 7% |
| Israel | 1 | 7% |
| Singapore | 1 | 7% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Lindus | Lindus Health's mission is to accelerate research for the next generation of health companies. | $18M | Series A | Aug 16, 2023 |  |
| thymia | We use video games based on Neuropsychology alongside analyses of video and speech to make mental health assessments smart, starting with depression.Our online platform empowers clinicians so they can assess depression faster, more accurately and objectively. Our multi-modal depression recognition and tracking system allows us to find the righttreatment in weeks instead of years and we make the entire process enjoyable for the patient. | $3.1M | Seed | Jul 27, 2023 |  |
| Loops | Loops is a no-code analytics platform that provides product and data teams with growth opportunities hidden in their data. | $10M | Seed | Nov 15, 2022 |  |
| Eden Bio | Harnessing nature's potential | $1.2M | Seed | Nov 14, 2022 |  |
| Exogene | Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost. | $2M | Pre-Seed | Apr 25, 2022 |  |
| Exogene | Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost. | $2M | Pre-Seed | Apr 25, 2022 |  |
| Exogene | Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost. | $2M | Seed | Apr 25, 2022 |  |
| Flexciton | Flexciton is an optimisation technology company that has developed a genuinely unique solution to radically improve the efficiency and productivity of fab manufacturing processes using cutting-edge AI technology. Flexciton enables more semiconductor wafers to be produced for the same cost, faster. Since being founded in May 2016, Flexciton hasrapidly expanded to a team of 45, the majority of whom are engineers and researchers with deep tech expertise.Manufacturing is critical to the human race; everything around us is manufactured. Human innovation has been enabled by manufacturing innovation. Manufacturing has stagnated because innovation has reached the limit of what human intelligence alone is capable of. Further innovation demands Artificial Intelligence.The company's vision is to bring Flexciton optimization technology to every factory in the world to enable manufacturing to operate at a level never before possible. | $20.5M | Series A | Jan 01, 2021 |  |
| Biomage | Biomage specializes in single-cell analysis transforming the life sciences. Our goal is to apply innovative computational methods to extract valuable insight from biological data, fueling cutting-edge research across biological disciplines.Our flagship product, the Biomage Single Cell Platform empowers researchers to take ownership of theirsingle cell data analysis, generating deep biological insight in just a few clicks. | $850K | Seed | Dec 08, 2020 |  |
| Qantev | AI claims platform for health & life insurance | $1.7M | Seed | Nov 12, 2020 |  |

10 of 15 investments shown.

## Co-investors
- [Entrepreneurs First](https://shizune.co/investors/profile/entrepreneur-first) — VC Fund, 5 deals together
- [BACKED VC](https://shizune.co/investors/profile/backed-vc) — VC Fund, 4 deals together
- [R42 Group](https://shizune.co/investors/profile/r42-group) — VC Fund, 3 deals together
- [Selvedge Venture](https://shizune.co/investors/profile/selvedge-venture) — VC Fund, 3 deals together
- [Calm/Storm VC](https://shizune.co/investors/profile/calm-storm-ventures) — VC Fund, 2 deals together
- [Entrepreneurs First](https://shizune.co/investors/profile/entrepreneurs-first) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Artificial intelligence Angel Investors in Europe](https://shizune.co/investors/artificial-intelligence-angel-investors-europe)
- [SaaS Angel Investors in United Kingdom](https://shizune.co/investors/saas-angel-investors-united-kingdom)
- [Artificial intelligence Angel Investors in United Kingdom](https://shizune.co/investors/artificial-intelligence-angel-investors-united-kingdom)
- [Biotech Angel Investors](https://shizune.co/investors/biotech-angel-investors)
- [Biotechnology Angel Investors](https://shizune.co/investors/biotechnology-angel-investors)
- [Biotech Angel Investors in United Kingdom](https://shizune.co/investors/biotech-angel-investors-united-kingdom)

## FAQ

### What does Nadav Rosenberg invest in?

Nadav Rosenberg invests primarily in Software, Biotechnology and Artificial Intelligence startups, most often at Seed and Pre-Seed stage. Most of the 15 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Nadav Rosenberg's check size?

Nadav Rosenberg typically joins rounds of $850k–$3.1M at Seed, $2M–$2M at Pre-Seed and $18M–$21M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Nadav Rosenberg participates in.

### When did Nadav Rosenberg last invest?

The most recent investment recorded for Nadav Rosenberg closed in Aug 2023. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co